Respiratory Syncytial Virus (RSV) Therapeutics Market Will Register a CAGR of +11% by 2023 – Know About Regional Outlook, Competitive Strategies, Technological Advancements by Top Players
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults. A RSV infection can lead to serious problems such as bronchiolitis and pneumonia. Rise in prevalence of RSV infection among infants and the increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection are likely to fuel the global respiratory syncytial virus (RSV) therapeutics market during forecast period.
View full press release